Juergen Eckhardt - 09 Jun 2026 Form 4 Insider Report for Metagenomi Therapeutics, Inc. (MGX)

Reporting relationship: Director
Issuer ticker: MGX
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 13:37:40 UTC
Prior SEC filing: 12 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew L. Wein, attorney-in-fact

Key filing fact

Juergen Eckhardt filed Form 4 for Metagenomi Therapeutics, Inc. (MGX) on 11 Jun 2026.

Key facts

This page summarizes Juergen Eckhardt's Form 4 filing for Metagenomi Therapeutics, Inc. (MGX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2026, 13:37.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001857806 Primary reporting owner

Eckhardt Juergen

Relationship: Director
Address: C/O METAGENOMI THERAPEUTICS, INC., 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE
Signature: /s/ Matthew L. Wein, attorney-in-fact
Signature date: 11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +21,000
Change %
Price: $0.000000^*
Shares after: 21,000
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,000
Exercise price: $1.23
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.